Show results for
  • Sygnature
  • News
  • Drug Discovery
  • Therapeutic Areas
  • Events
  • Vacancies

Sygnature Discovery at BioJapan 2017 – Participating in UK Department of International Trade Mission

Sygnature Discovery, the UK’s largest independent provider of integrated drug discovery resource and expertise, is participating in BioJapan 2017 from 11th – 13th October 2017 in Yokohama.  Sygnature is part of a UK Department of International Trade (UK DIT) Mission and is located on the UK Pavilion (Booth No. C-48).

The Sygnature Discovery BioJapan team is being led by Dr Steve Young, VP, Business Development.  He is accompanied by Dr Mihiro Sunose, Principal Scientist, Chemistry, and Dr Hiroki Wada, Senior Scientist, Chemistry.

Dr Young commented, “Sygnature Discovery sees a great business opportunity to collaborate with pharmaceutical and biotechnology companies located in Japan.  We are already working with a number of Japanese companies and our integrated service-offering co-located in our new, purpose-built facility at BioCity Nottingham has been beneficial to their projects.  In addition, having Mihiro and Hiroki as part of our team enables us to communicate effectively with our clients in Japan.  We are pleased to be part of the UK DIT mission and anticipate a successful time at BioJapan 2017.”

As well as taking part in BioJapan 2017, the Sygnature team will also be meeting with clients and potential clients whilst in Japan.

Latest News

View All

Sygnature Discovery moves US base to Kendall…

Sygnature Discovery raises over £2,776 for Cancer…

Sygnature Discovery named as Finalist in 2019…

Hidden chemistry in flowers shown to kill…

Get in Touch

For more details on how we can provide innovative support to your project please use this contact form.

CTA Form

The information you supply will be processed in accordance with the General Data Protection Regulation (EU) 2016/679. For further details about how Sygnature Discovery collects, uses and stores personal data, please refer to our Website Privacy Notice available here.